Literature DB >> 20308374

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.

Michael R Jacobs1, Caryn E Good, Anne R Windau, Saralee Bajaksouzian, Donald Biek, Ian A Critchley, Helio S Sader, Ronald N Jones.   

Abstract

The in vitro activity of ceftaroline against 891 pneumococci collected in 2008 from 22 centers in the United States was investigated. Ceftaroline was the most potent agent tested, with the MICs being <0.008 to 0.5 microg/ml and the MIC(90)s being <0.008 to 0.25 microg/ml against 11 prevailing serotypes. The overall rates of susceptibility were as follows: penicillin G, 86.2%; ceftriaxone, 90.7%; cefuroxime, 70.1%; erythromycin, 61.6%; clindamycin, 79.2%; levofloxacin, 99.4%; and vancomycin, 100%. Serotype 19A isolates were the least susceptible. These results support the use of ceftaroline for the treatment of pneumococcal infections, including those caused by pneumococci resistant to other agents.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20308374      PMCID： PMC2876371          DOI： 10.1128/AAC.01797-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Genetic basis for the new pneumococcal serotype, 6C.

Authors:  In Ho Park; Saeyoung Park; Susan K Hollingshead; Moon H Nahm
Journal:  Infect Immun       Date:  2007-06-18       Impact factor: 3.441

2.  Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-02-15       Impact factor: 17.586

3.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Authors:  Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

4.  In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.

Authors:  Yigong Ge; Donald Biek; George H Talbot; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

5.  Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

Authors:  Lauri A Hicks; Lee H Harrison; Brendan Flannery; James L Hadler; William Schaffner; Allen S Craig; Delois Jackson; Ann Thomas; Bernard Beall; Ruth Lynfield; Arthur Reingold; Monica M Farley; Cynthia G Whitney
Journal:  J Infect Dis       Date:  2007-10-04       Impact factor: 5.226

6.  Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience.

Authors:  Michael R Jacobs; Caryn E Good; Bernard Beall; Saralee Bajaksouzian; Anne R Windau; Cynthia G Whitney
Journal:  J Clin Microbiol       Date:  2008-01-30       Impact factor: 5.948

7.  In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.

Authors:  Cédric Jacqueline; Jocelyne Caillon; Virginie Le Mabecque; Anne-Françoise Miègeville; Antoine Hamel; Denis Bugnon; James Yigong Ge; Gilles Potel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191

8.  Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.

Authors:  Michael E Pichichero; Janet R Casey
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

9.  Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005.

Authors:  Allison F Messina; Kathy Katz-Gaynor; Theresa Barton; Naveed Ahmad; Faryal Ghaffar; David Rasko; George H McCracken
Journal:  Pediatr Infect Dis J       Date:  2007-06       Impact factor: 2.129

10.  Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.

Authors:  Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191
View more
  18 in total

Review 1.  Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Authors:  Thomas P Lodise; Donald E Low
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

Review 2.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

3.  Pneumonia Due to Drug-Resistant Streptococcus pneumoniae.

Authors:  Sadao Jinno; Michael R Jacobs
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

4.  In vivo efficacy of ceftaroline fosamil in a methicillin-resistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model.

Authors:  Delphine Croisier-Bertin; Davy Hayez; Sonia Da Silva; Delphine Labrousse; Donald Biek; Cedric Badiou; Oana Dumitrescu; Pascal Guerard; Pierre-Emmanuel Charles; Lionel Piroth; Gerard Lina; Francois Vandenesch; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

5.  Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States.

Authors:  Sandra S Richter; Daniel J Diekema; Kristopher P Heilmann; Cassie L Dohrn; Fathollah Riahi; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

6.  In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

Authors:  James A Karlowsky; Heather J Adam; Melanie R Decorby; Philippe R S Lagacé-Wiens; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

7.  Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Christopher Duplessis; Nancy F Crum-Cianflone
Journal:  Clin Med Rev Ther       Date:  2011-02-10

8.  In vitro activity of ceftaroline against clinical isolates of Streptococcus pneumoniae recovered in 43 U.S. medical centers during 2010-2011.

Authors:  Gary V Doern; Daniel J Diekema; Kristopher P Heilmann; Cassie L Dohrn; Fathollah Riahi; Sandra S Richter
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

9.  Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.

Authors:  Robert K Flamm; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

10.  Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.

Authors:  David Oldach; Kay Clark; Jennifer Schranz; Anita Das; J Carl Craft; Drusilla Scott; Brian D Jamieson; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.